CoronaryAtlas logo
CoronaryAtlas
Ceramide (24:0)
Pathway / Lipid retention & oxidation

Ceramide (24:0)

lipid

Ceramide (24:0) accumulates in atherosclerotic lesions and predicts adverse cardiovascular outcomes through altered lipid metabolism and plaque composition.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleCeramide accumulation in atherosclerotic plaques; sphingolipid dysregulation in CAD.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
67
A — assay feasibility
40
E — evidence strength
66
T1DI (composite)
13
Specificity differential (R−C)+0.3
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 2
2hypovolemia / dehydrationmag 2
2tachyarrhythmian/a
2hypoxemia / respiratory failuremag 2
2hypertensive emergencyn/a
2high-demand / peri-operative stressn/a
3sudden cardiac deathn/a
4aPCI-related periproceduraln/a
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedn/a
Coverage: 4/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 11 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(1)